Page last updated: 2024-12-08
beauverolides
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
beauverolides: beauverolides H & I have been encountered in our literature; cyclodepsopeptide from the entemopathogenic fungus Beauvaria bassiana Bals; RN given refers to beauverolide H [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 194155 |
MeSH ID | M0061930 |
Synonyms (7)
Synonym |
---|
62995-90-8 |
beauverolides |
cyclo-((r)-beta-hydroxynonanoyl-l-phenylalanyl-alanyl-d-leucyl) |
beauverolide h |
d-leucine, n-(n-(n-(3-hydroxy-1-oxononyl)-l-phenylalanyl)-l-alanyl)-, lambda-lactone, (r)- |
9-benzyl-13-hexyl-5,8,11-trihydroxy-6-methyl-3-(2-methylpropyl)-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one |
DTXSID10978882 |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" We show that the fungal natural products beauveriolides I and III can potently decrease Abeta secretion from cells expressing human amyloid precursor protein; this offers a potential new scaffold for the development of compounds with proven bioavailability for the treatment of AD." | ( The natural products beauveriolide I and III: a new class of beta-amyloid-lowering compounds. Boldt, GE; Chen, Y; Rogel, JK; Wentworth, P; Witter, DP, 2009) | 0.35 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (28)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (14.29) | 18.2507 |
2000's | 13 (46.43) | 29.6817 |
2010's | 8 (28.57) | 24.3611 |
2020's | 3 (10.71) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.40
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.40) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (3.45%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 28 (96.55%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |